Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information | Modern Pathology
JCI - FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease
Initial Treatment Decisions | Breast Surgery Specialist Melbourne, VIC
Luminal B Breast Cancer - an overview | ScienceDirect Topics
Les 12 questions les plus souvent posées sur le cancer du #sein en consultation - HC Ceuta, Centro Médico de Especialidades | Centro Médico de Especialidades
Comprendre le cancer du sein (2/5) – Allaitement, bonheur et raison
Cancer du sein luminal et apport des classifications intrinsèques moléculaires : comment identifier les tumeurs luminales A et B en 2015 ? - ScienceDirect
Table 2 from Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 | Semantic Scholar
Heterocellular gene signatures reveal luminal-A breast cancer heterogeneity and differential therapeutic responses | npj Breast Cancer
PDF) Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives A B
Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar
Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression | Molecular Diagnosis & Therapy
Frontiers | High Parity Predicts Poor Outcomes in Patients With Luminal B-Like (HER2 Negative) Early Breast Cancer: A Prospective Finnish Single-Center Study
Table 2 from Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar
PDF) Luminal B Breast Cancer: Molecular Characterization, Clinical Management, and Future Perspectives A B
KoreaMed Synapse
Breast tumor subtype definition in Kenyan breast cancer patients... | Download Scientific Diagram
Cancer du sein: la pathologie, pierre angulaire de la décision thérapeutique
![PDF] Breast cancer recurrence according to molecular subtype. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/a61e3d01d68b219c10d07ee87bccd224d32fcf2b/3-Table1-1.png "PDF] Breast cancer recurrence according to molecular subtype. | Semantic Scholar")
PDF] Breast cancer recurrence according to molecular subtype. | Semantic Scholar
Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors
JPM | Free Full-Text | Correlation between Androgen Receptor Expression in Luminal B (HER–2 Negative) Breast Cancer and Disease Outcomes
A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer (AJCC) cancer staging system for luminal A breast cancer - Chinese Journal of Cancer Research
pCR After Neoadjuvant Chemotherapy in Luminal B Breast Cancer | Download Table
Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype | BMC Research Notes | Full Text
